News Conference News TCT 2024 Pooled All-Female Analysis Support Benefits of TAVI Over SAVR L.A. McKeown November 01, 2024
News Conference News TCT 2023 LIFE-BTK: Bioresorbable Scaffold Holds Promise for Infrapopliteal CLTI L.A. McKeown October 25, 2023
News Conference News TCT 2023 Paclitaxel Safety Questions in PAD: Will ‘Capstone’ Data Close the Door? L.A. McKeown October 24, 2023
News Conference News SCAI 2023 CLIPPER Attempts to Draw Out Useful Quality Metrics for CLTI L.A. McKeown May 25, 2023
News Conference News SCAI 2023 Real-World CLTI Patients, Outcomes Are a Departure From BEST-CLI L.A. McKeown May 24, 2023
News Conference News AHA 2022 Long-Awaited BEST-CLI Results Favor Surgery Over Endovascular Therapy in CLTI L.A. McKeown November 07, 2022
News Conference News VIVA 2022 ‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups L.A. McKeown November 04, 2022
News Conference News ESC 2022 DANCAVAS: Food for Thought as CV Screening in Older Men Misses Mark L.A. McKeown August 30, 2022
News Conference News ACC 2020 New Questions About Triple Therapy After PAD Revascularization: VOYAGER PAD Substudy L.A. McKeown April 02, 2020
News Conference News ACC 2020 VOYAGER PAD: Rivaroxaban Bests Aspirin Alone for Preventing Limb and CV Events L.A. McKeown March 28, 2020
News Conference News VIVA 2018 Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease L.A. McKeown November 15, 2018